GLMD News
Archived Headlines
- Biotechs post better returns this week before an IPO tech wave 03/13/14
- Galmed Pharmaceuticals prices upsized IPO at $13.50, within the range 03/13/14
- 6 US IPOs planned for the week of Mar 10 03/10/14
- US IPO Recap: Varonis provides data security for enterprises and financial security for investors 03/03/14
- Liver disease biotech Galmed sets terms for $31 million IPO 02/28/14
See more
Immunotherapy biotech Tobira Therapeutics sets terms for $60 million IPO; researching HIV and NASH
Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $60 million by offering 4.6 million shares at a price range of $12 to...read more
Immunotherapy biotech Tobira Therapeutics files for a $69 million IPO to treat NASH and HIV
Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, filed on Monday with the SEC to raise up to $69 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2006, plans to...read more
Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO
Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on...read more
US IPO Recap: Castlight Health's 149% pop shows healthy tech demand
Castlight Health (CSLT) completed the fourth technology IPO of the year, and its 149% first day return brought the sector's average up to 95% for 2014. Castlight was also the ...read more